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BACKGROUND: The mammalian target of rapamycin (mTOR) is an important therapeutic target in the treatment of renal cell carcinoma
(RCC). Pre-clinical data indicate that the combined inhibition of both the epidermal growth factor receptor and mTOR results in
enhanced anticancer activity.
METHODS: All patients had metastatic RCC with progression after treatment with sunitinib and/or sorafenib. Treatment consisted of
erlotinib 150mg orally once a day starting on day 1 and sirolimus 6mg orally on day 8 followed by 2mg daily, adjusted according to
blood levels.
RESULTS: A total of 25 patients were enrolled between July 2006 and March 2008. The median progression-free survival (PFS) was
12 weeks (95% CI 5.9–18.1) and median overall survival (OS) 40 weeks (95% CI 0–85.7). No confirmed complete or partial
responses were observed, but stable disease 46 months was noted in 21.8% (95% CI 4.9–38.6) of patients. The most common
adverse events were rash and diarrhoea. There was no correlation between erlotinib, OSI-420 (days 8 and 15) or sirolimus
(days 15 and 29) blood levels and PFS or OS.
CONCLUSIONS: The combination of sirolimus and erlotinib for RCC failed to demonstrate an advantage over available single-agent
therapy in the second-line setting.
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Renal cell carcinoma (RCC) affects near 58000 individuals in the
United States every year, and metastatic disease causes nearly
13000 deaths annually (Jemal et al, 2009). With the exception of a
small proportion of selected patients treated with high-dose
interleukin-2 (McDermott et al, 2005) or allogeneic hematopoietic
stem cell transplantation (Childs et al, 2000), metastatic RCC
remains an incurable condition.
In the majority of cases of RCC, functional inactivation of the
von Hippel–Lindau (VHL) gene leads to overexpression of
hypoxia inducible factor (HIF)-1a and HIF-2a resulting in
overproduction of vascular endothelial growth factor (VEGF)
and transforming growth factor (TGF)-a (Kim and Kaelin, 2006).
The development of oral inhibitors of the kinase activity of the
VEGF receptors, namely sunitinib (Motzer et al, 2007) and
sorafenib (Escudier et al, 2007), represent a major therapeutic
advancement in the treatment of RCC. The best response to multi-
kinase inhibitors is often temporary disease stabilisation, although
long-term clinical response is seen in a small number of patients.
The mammalian target of rapamycin (mTOR) is a serine–
threonine kinase implicated in cellular growth and proliferation. It
is regulated directly or indirectly by growth factor receptors and
cell signalling pathways known to be overstimulated in RCC,
particularly the PI3 kinase pathway (Guertin and Sabatini, 2007).
Two analogues of sirolimus (rapamycin), temsirolimus (Hudes
et al, 2007) and everolimus (Motzer et al, 2008), have shown
clinical activity in metastatic RCC as initial treatment of high-risk
disease and after failure of a multi-kinase inhibitor, respectively.
As TGF-a overproduction and consequent stimulation of the
epidermal growth factor receptor (EGFR) is a hallmark of most
RCC tumours (Gunaratnam et al, 2003; Gemmill et al, 2005;
Costa et al, 2007), EGFR inhibitors (such as erlotinib and gefitinib)
have a theoretical role in the treatment of RCC, on the basis of
our understanding of the pathophysiology. In previous work, our
group has demonstrated in vitro synergistic activity between
mTOR inhibitors and EGFR inhibitors at concentrations that are
achievable in vivo, providing the rationale for this clinical study
(Gemmill et al, 2005; Costa et al, 2007).
In this study, we provide the mature results of a single-
institution phase II trial examining the clinical activity of the
combination of sirolimus and erlotinib in a pretreated population
of RCC patients. Received 4 May 2010; revised 22 July 2010; accepted 2 August 2010
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sMATERIALS AND METHODS
This was a phase II, single-arm, single-institution trial. The
primary objective was to evaluate the efficacy of the combination
of sirolimus and erlotinib as determined by progression-free
survival (PFS). Secondary objectives were evaluation of the safety
and tolerability of the combination, response rate, overall survival
(OS) and the influence of sirolimus on the blood levels of erlotinib
as well as correlation between drug levels and antitumour activity.
Patients
All patients had a histological diagnosis of RCC, life expectancy
of 43 months, an ECOG performance status of 0–2, measurable
disease, progression after or intolerance to sorafenib and/or
sunitinib, and adequate bone marrow function (haemoglobin
of X9g per 100ml, platelets of X100000 10
9 and an absolute
neutrophil count of X1500mm
3). The exclusionary criteria
included previous treatment with erlotinib, gefitinib, sirolimus,
temsirolimus or everolimus, untreated central nervous system
metastasis, renal failure requiring dialysis or significant liver
dysfunction (AST, ALT, total bilirubin or alkaline phosphatase
41.5 the upper limits of normal). The protocol was approved by
the Colorado multiple institutional review board and all partici-
pants provided written informed consent before study enrollment.
The study was registered on ClinicalTrials.gov (Identifier:
NCT00353301).
Treatment
Erlotinib (Tarceva, Genentech USA, South San Francisco, CA,
USA) therapy was started at 150mg by mouth daily from day 1 to
be taken at least 1h before or 2h after a meal. Sirolimus was
initiated on day 8 (D8) with a loading dose of 6mg by mouth,
followed by a daily dose of 2mg by mouth, on the basis of the
product prescribing information for low-to-moderate immunolo-
gic risk renal transplant patients. The levels of erlotinib and its
primary metabolite, OSI-420, were assessed after the initial 7 day
run-in and after 1 week of combined therapy (i.e., on days 8 and
15). Erlotinib levels were not used to make clinical decisions.
Trough levels of sirolimus were checked on day 15 (D15) and then
monthly and maintained between 4 and 20ngml
–1. The sirolimus
dose was also reduced because of any significant toxicity attributed
to sirolimus. Treatment was continued until progression, unac-
ceptable toxicity, withdrawal of consent or investigator’s decision
to discontinue therapy.
All participants had measurable disease with repeated computed
tomography or magnetic resonance imaging scans every 8 weeks
while on the study. A bone scan was assessed at baseline and
followed in those with bone disease at baseline or in any patient
with new bone symptoms. Physical exams, toxicity assessments
and laboratory assessments (including electrolytes, kidney func-
tion, liver function, complete blood count and fasting lipids) were
obtained every 4 weeks.
Progression was defined as radiographic progression according
to RECIST criteria (year 2000 version), non-compliance in
obtaining scans, unequivocal clinical progression or the initiation
of another medication for the treatment of RCC. The safety of this
combination was assessed through the compilation and grading of
all adverse events (AEs) according to the common terminology
criteria for AEs v3.0.
Erlotinib and OSI-420 analysis in human plasma by
LC/MS/MS
Erlotinib and OSI-420 were measured in human plasma using
a validated LC/MS/MS assay based on a previously published
method with midazolam as an internal standard (Zhao et al,
2003). OSI-420 is an active metabolite of erlotinib. Positive ion
electrospray ionisation mass spectra were obtained with a MDS
Sciex 3200 Q-TRAP triple quadrupole mass spectrometer (Applied
Biosystems, Inc., Foster City, CA, USA) with a turbo ionspray
source interfaced to an Agilent 1200 Series Binary Pump SL HPLC
system (Santa Clara, CA, USA). Samples were chromatographed
with an XBridge Phenyl, 2.5mm, 4.6 50mm column (Waters
Corporation, Milford, MA, USA) protected by a C18 guard
cartridge, 4.0 2.0mm (Phenomenex, Torrance, CA, USA). An
LC gradient was used with mobile phase A consisting of 10mM
ammonium acetate and mobile phase B consisting of acetonitrile.
Chromatographic separation was achieved by increasing mobile
phase B linearly from 30 to 98% from 0 to 1.75min, maintaining at
98% from 1.75 to 2.25min, decreasing linearly from 98 to 30%
from 2.25 to 2.5min, followed by re-equilibration of the column
at 30% mobile phase B from 2.5 to 3min. The LC flow rate was
1.3mlmin
–1, the sample injection volume was 5ml and the analysis
run time was 3min.
The mass spectrometer settings were optimised as follows: turbo
ionspray temperature, 6501C; ion spray voltage, 2000V; decluster-
ing potential, 50V; entrance potential (EP), 10V; collision energy,
45V (Erlotinib and OSI-420) and 39V (midazolam); collision
cell EP, 150V (Erlotinib and OSI-420) and 35V (midazolam);
collision cell exit potential, 5V (Erlotinib and midazolam) and
10V (OSI-420); curtain gas, N2, (CUR), 30 units; collision gas,
N2, (CAD), medium; nebuliser gas, N2, 60 units; and auxiliary gas,
N2, 60 units. Samples were quantified by internal standard
reference method in the MRM mode monitoring ion transitions
m/z 394-278a.m.u. for erlotinib, m/z 380-278a.m.u. for OSI-420
and m/z 326-291a.m.u. for the internal standard, midazolam.
Each ion transition was integrated for 200ms and Q1 and Q3 were
both operated in unit resolution mode.
Analytical standards, quality control (QC) and unknowns were
all prepared by adding 200ml of unknown or spiked blank plasma
samples to a 1.5ml microcentrifuge tube containing 10mlo f
10mgml
–1midazolam solution followed by brief vortexing. Plasma
proteins were then precipitated by the addition of 800mlo f
acetonitrile followed by 10-min vortex mixing. Samples were then
centrifuged at 18000 RCF for 10min and the supernatant collected
and transferred to autosampler vials for analysis. Erlotinib,
OSI-420 and midazolam standard solutions were prepared in
50% acetonitrile in water. The lower and upper limits of quanti-
tiation for the assay were 0.5 and 5000ngml
–1, respectively.
Accuracy and precision (% RSD) based on analysis of QC samples
for this assay was 96.5 and 3.4% for erlotinib and 96.8 and 1.9% for
OSI-420.
Statistical analysis
A sample size of 25 patients was calculated to provide 80% power
to detect an improvement in PFS from 12 to 24 weeks in this
population. Progression-free survival and OS with their respective
95% CI were calculated using the method of Kaplan–Meier.
Comparison between drug levels on days 8 and 15 was performed
using Wilcoxon signed-rank test. Drug levels between patients who
had stable disease (SD) and patients who had progressive disease
as their best response were compared using Mann–Whitney
U-test. All statistical inferences were based on a P-value of o0.05.
RESULTS
Patient characteristics
Enrollment started in July 2006 with the last patient accrued in
March 2008. A total of 27 patients were screened of which 25 were
found to be eligible and continued to treatment. The median
subject age was 60 years (range of 47–73 years), with an average
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histologically confirmed RCC with 19 having predominantly
clear cell type (Table 1). Data were gathered and analysed in
October 2009 with the median follow-up of surviving patients
being 117 weeks.
Efficacy
Two patients withdrew consent before first response assessment or
obvious progression. These patients are assessed for toxicity but
not for efficacy. The median PFS was 12 weeks (95% CI 5.9–18.1)
as displayed in Figure 1. The median OS was 40 weeks (95% CI
0–85.7, Figure 2). There were no objective responses according
to RECIST criteria; however, 13 patients had SD beyond 8 weeks
(56.5%, 95% CI 36.3–76.8) and of these, 5 (21.8, 95% CI 4.9–38.6)
had SD lasting longer than 6 months. One subject had SD lasting
80þ weeks and was still on therapy at the time of this report. An
analysis of best response by RECIST criteria indicates that 7 of 25
patients had a reduction in their RECIST measurements from
baseline, ranging from a 1.8 to 17.0% reduction.
Several patients had notable reduction in the size of some
tumours, although none of these reductions met the RECIST
criteria for a partial response. Figure 3 shows an example of a
significant reduction in the size of two pelvic tumours, although
tumours in the patient’s abdomen later grew during the course
Table 1 Patient characteristics
Number of treated patients 25
Median age 60 years
Age range 47–73 years
Mean number of previous treatments 2.6
Previous treatment number range 1–6
Previous sunitinib treatment 22
Previous sorafenib treatment 19
Previous bevacizumab treatment 5
Histology distribution
Clear cell carcinoma (predominant) 19
Clear cell with sarcomatoid features 3
Unclassified/other renal cell carcinoma 3
Progression-free survival
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Figure 1 Kaplan–Meier estimate of the PFS.
Overall survival
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Figure 2 Kaplan–Meier estimate of the OS.
Baseline Cycle 11
Figure 3 (A) Evidence of tumour response. Soft tissue pelvic mass measuring 55mm at baseline (left panel) vs 30mm at cycle 11 (right panel); (B)a
second pelvic mass in the same patient, 50mm at baseline and 34mm at cycle 11. Other target lesions were stable and this subject did not meet RECIST
criteria for a partial response.
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48 weeks with SD.
Toxicity
Frequent and severe AEs are displayed in Table 2. The most
common AE observed was rash, consistent with the rash associated
with single-agent erlotinib use and observed in 24 patients.
It was generally mild-to-moderate (19 of 24 cases were grade 1
or 2) and centred on the face and upper thorax. Diarrhoea was
also frequently encountered, observed in 12 subjects, although it
was grade 1 in 10 of the 12. Special attention was paid
to hypertriglyceridaemia, as this is a known side effect of
sirolimus. It was noted in 9 of the 25 subjects, without clear
clinical symptoms (e.g., pancreatitis) in any participant. Overall,
the most common grade 3 and 4 toxicities (at least 2 incidences)
included: rash, anaemia, mucositis, hypoalbuminaemia, and
hypophosphataemia. Two subjects died during the study period.
One patient discontinued therapy and died of disease progression
during the 30-day safety window. Another patient stopped
treatment 7 days before a planned tumour debulking and died in
the postoperative period.
Drug levels and efficacy
The levels of erlotinib and its active metabolite OSI-420 were
assessed on D8 and on D15 of cycle 1. D8 values were available for
24 subjects and D15 values for 22 subjects. The introduction of
sirolimus on D8 did not cause any significant change in blood
levels of erlotinib (P¼0.54) or in the levels of OSI-420 (P¼0.60),
comparing D8–D15. Neither D8 erlotinib (P¼0.72), D15 erlotinib
(P¼0.40), D8 OSI-420 (P¼0.48), D15 OSI-420 (0.89), D15
sirolimus (P¼0.99) nor D29 sirolimus (P¼0.25) correlated with
PFS. Similarly, neither D8 erlotinib (P¼0.23), D15 erlotinib
(P¼0.11), D8 OSI-420 (P¼0.44) D15 OSI-420 (P¼0.17), D15
sirolimus (P¼0.64) nor D29 sirolimus (P¼0.48) correlated with
the OS. An analysis of the erlotinib, OSI-420 and sirolimus drug
levels with respect to the best response to therapy, showed no
correlation (Table 3).
DISCUSSION
Since the initiation of this study, two mTOR inhibitors have been
approved by the US Food and Drug Administration for the
treatment of RCC (Hudes et al, 2007; Motzer et al, 2008).
Temsirolimus and interferon were evaluated in the first-line RCC
setting, specifically including patients with poor clinical prognostic
factors (Hudes et al, 2007). Single-agent temsirolimus demon-
strated a 3.5-month median survival advantage (7.3 vs 10.9
months), compared with interferon. More recently, an oral mTOR
inhibitor, everolimus, was compared with placebo in the treatment
of RCC after failure of a tyrosine kinase inhibitor (Motzer et al,
2008). The final results of this trial have now been released,
showing a persistent benefit from everolimus as measured by PFS
(4.9 vs 1.9 months), but not by OS (Motzer et al, 2010). The
objective response rate in the final analysis was 1.8% with
everolimus vs 0% with placebo, although 47% of everolimus-
treated patients had some reduction in tumour size from baseline,
vs only 10% of subjects in the placebo arm. In this study, 7 of 25
(28%) of the patients had some reduction in tumour, by RECIST
measurements. Unlike the multi-targeted tyrosine kinase inhibi-
tors, such as sunitinib and sorafenib, which target a complex array
of different enzymes, sirolimus, temsirolimus and everolimus
share a single target (mTOR) and are closely related in structure
and activity. It remains unclear what advantages any of these
individual agents may possess over the others in this class.
This study demonstrates the safety and feasibility of treatment
combining EGFR and mTOR inhibition in a pretreated cohort of
advanced RCC patients. We were unable to prove a median PFS
superior to 12 weeks, the main hypothesis stated in the study
design. Indeed, a median PFS of 1.9 months was seen in the
placebo-treated control arm of a trial accruing a similar population
of RCC patients (Motzer et al, 2008). This suggests that we may
have failed to reject the null hypothesis because we overestimated
Table 2 Adverse events
Symptoms
Grade
1
Grade
2
Grade
3
Grade
4 Total
Dermatology/skin
Rash 16 3 5 24
Dry skin 7 1 8
Pruritis/pain 4 2 6
Haematologic/lab
Anaemia 2 7 5 14
GI
Diarrhoea 10 1 1 12
Anorexia 7 2 9
Mucositis 4 3 2 9
Nausea 7 1 8
Metabolic/lab
Hypoalbuminaemia 9 3 12
Elevated creatinine 6 3 1 10
Hypertriglyceridaemia 2 6 1 9
Hypophosphataemia 2 3 2 7
Constitutional
Fatigue 9 2 11
Pain 5 2 7
Chills/cold intolerance 6 6
Weight loss 6 6
Pulmonary
Cough 7 7
Rhinitis 7 7
Pulmonary oedema 1 1
Haemorrhage/bleeding
Haemorrhage/bleeding other 6 6
Epistaxis 6 6
Cardiac
Decreased LVEF 1 1
MI 1 1
Tachycardia 1 1
Anuria 1 1
Abbreviations: GI¼Gastrointestinal; LVEF¼Left ventricular ejection fraction;
MI¼myocardial infarction. All serious adverse events or adverse effects experienced
by six or more patients are listed above with or without attribution to study
medications.
Table 3 Drug and metabolite levels according to best response
Stable disease
(ngml
–1)
Progressive disease
(ngml
–1) P-value
D8 erlotinib 1792 2201 0.2
D15 erlotinib 1853.5 1652.5 0.74
D8 OSI-420 154.5 193 0.18
D15 OSI-420 155.5 131 0.91
D15 sirolimus 11.5 9.5 0.65
D29 sirolimus 7.0 8.1 0.46
Abbreviations: D8¼day 8 of cycle 1; D15¼day 15 of cycle 1; D29¼day 29 of
cycle 1. It is to be noted that two subjects withdrew consent before the first imaging
assessment or progression and are not included; therefore the total number of
subjects analysed in this assessment is 23.
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study combination. However, a proportion of patients in the
current trial obtained prolonged SD, 21.8% at 6 months, which
compares with approximately 35 and 10% in the everolimus and
placebo arms of the phase III trial at 6 months, respectively
(Motzer et al, 2010).
The clinical significance of EGFR inhibition in RCC remains
uncertain. Several lines of evidence including a strong mechanistic
rationale and preclinical data support the importance of the EGFR
pathway in RCC. Specific work directly endorses a synergistic role
for EGFR and mTOR inhibition in RCC cells in vitro (Gemmill
et al, 2005; Costa et al, 2007). There are now several completed
trials examining EGFR blockade in RCC. The activity of gefitinib as
a single-agent has been evaluated in RCC patients with metastatic
disease with no objective responses observed (Jermann et al, 2006).
The median time to progression was 110 days, but the significance
of this finding is difficult to assess without a control arm. A
separate investigation of single-agent gefitinib in advanced RCC
sought to correlate EGFR protein expression to clinical response
(Dawson et al, 2004). A total of 21 patients were treated without
any objective responses, yielding a median PFS of 2.7 months.
There was no correlation between EGFR status and the PFS. In
contrast, lapatinib, a dual-EGFR/ErbB2 inhibitor, was shown to
improve OS specifically in the subset of RCC patients with elevated
EGFR expression (Ravaud et al, 2008). EGFR inhibitors have also
been combined with other anti-vascular agents. Bukowski et al
(2007) randomised 104 patients with RCC to bevacizumab with or
without erlotinib in the first-line setting. Although well tolerated,
the combination treatment did not yield any improvement in PFS
over bevacizumab alone. Thus, on the basis of our results and
these studies, we suggest that future investigation of EGFR
inhibitors in RCC should focus on the subset of tumours that
overexpress (or have mutated) ERB-B receptors. As demonstrated
in clinical studies of EGFR inhibitors in lung cancer, the benefit of
EGFR-targeted therapies may not be apparent in unselected
patients (Herbst et al, 2004), while marker-positive patients may
have significant benefit (Maemondo et al, 2010).
Recent studies have demonstrated that while rapamycin
effectively inhibits mTORC1-mediated phosphorylation of p70S6
kinase and its substrates, inhibition of 4E-BP1 in mammalian cells
is frequently deficient (Thoreen et al, 2009). This is in distinct
contrast to rapamycin-mediated Tor inhibition in yeast. Therefore,
it is likely that the degree of mTOR inhibition obtained with the
current agents in human cancers, including RCC, is insufficient.
With the recent approval of six targeted agents for the treatment
of RCC, clinicians now face a therapeutic dilemma in selecting the
most appropriate agent for an individual RCC patient. Unlike
other cancer types in which predictive biomarkers exist for
targeted therapies (e.g., HER2/neu in breast cancer), therapeutic
decision-making in RCC relies on rudimentary and largely clinical
measures including performance status, past treatments and
histology. To make the best use of our current therapeutic tools,
new predictive biomarkers must be validated in RCC in carefully
designed trials able to discriminate between prognostic and
predictive markers. In this arena, the VHL mutational status has
been correlated in the preclinical setting to responses with mTOR
and EGFR inhibition, with wt-VHL demonstrating enhanced
activity (Gemmill et al, 2005). One limitation of this study is the
lack of VHL mutational status assessment. It is also notable that
there is very limited evidence suggesting that activating EGFR
mutations may be present in RCC and predict for EGFR tyrosine
kinase inhibition responses (Iyevleva et al, 2009). Such mutations
were not assessed in this study.
In summary, the combination of erlotinib and sirolimus has an
acceptable safety profile in RCC, considering the advanced disease
state of the subjects in this trial. Although no objective responses
were noted, prolonged SD was observed in a small number of
patients; however, the combination failed to demonstrate an
advantage over single-agent everolimus in this setting. The clinical
importance of EGFR blockade and the relative effectiveness of any
one of the available mTOR inhibitors over another in RCC remain
uncertain, although the use of sirolimus would represent a
considerable cost savings.
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